Information for Investors

Attomarker Business Summary

About Attomarker

Attomarker is a UK diagnostics company developing rapid multiplex immunoassays capable of quantifying multiple biomarkers from a single, low-volume blood sample. Our initial focus is on immune function and infectious diseases, providing high-precision quantified measurements at the Point of Care, to laboratory standards, in as little as 7 minutes, to support clinical care, disease investigation, and research.

Our beachhead commercial focus is Long Covid, where clinicians require tools to understand persistent symptoms, immune dysfunction, and recovery patterns. Our portfolio is designed to address these needs through rapid, accurate immune profiling, including with our UKCA COVID Antibody Spectrum Test characterising Long Covid patients into clinically meaningful endotypes to target interventions and monitor recovery.

Attomarker’s technology is supported by peer-reviewed publications, variant-specific antibody research, and a development pathway enabling rapid expansion into adjacent diagnostic markets. It is protected by 8 granted patents.

Beachhead Market: Long Covid and Immune Status Diagnostics

Long Covid represents a significant global health challenge, and an enormous social burden, with sufferers lives and employment often devastated by seemingly intractable and debilitating symptoms. Published data indicates:

Demand for diagnostic clarity remains high. Clinicians require tools to assess immune response quality, identify immune deficits or hyperstimulation, and support interpretation of persistent symptoms, all to allow clinically appropriate treatment choices.

Attomarker’s first commercial assays are designed specifically for this market.

Covid Antibody Spectrum Test

Our Covid Antibody Spectrum Test has a UKCA mark and is currently available through Attomarker’s laboratory, as well as on a research or compassionate use basis in other territories.

The test measures:

across 15 SARS-CoV-2 variants, including multiple Omicron lineages, Delta, and ancestral strains.

CoAST allows classification of patients into immune endotypes:

which support clinical evaluation of ongoing symptoms, targeting treatments and recovery monitoring.

Companion Immune Diagnostics for Long Covid

Attomarker is developing a suite of additional immune function tests that complement our antibody spectrum test and expand diagnostic insight for Long Covid and similar post-viral conditions. These include:

Each test leverages the same underlying multiplex biochemical measurement platform, enabling efficient development and scalable deployment.

This portfolio forms a unified diagnostic ecosystem for Long Covid and post-viral syndromes.

Attomarker Pipeline Information

Pipeline: Extension of Immune Diagnostics into Further Post-viral & Autoimmune Conditions

Attomarker has signed a co-development agreement with EpitogenX to leverage our technology platform and immune diagnostics expertise with Epitogen’s antigen discovery & development capability. This will enable the extension of our platform approach into:

According to Grand View Research, the global Lyme disease testing market is was valued at USD $10.85 billion in 2023, and is set to rise to USD $18.57 billion by 2030. It has the same under-served diagnostic characteristics as Long Covid.

According to Delve Insight, the Hashimoto’s thyroiditis market size (diagnostics and treatment) in the seven major markets is expected to grow from USD $2.22 billion in 2025 to USD $2.80 billion in 2034, with 20 million diagnosed prevalent cases. Again, it is underserved diagnostically.

Read more about the Attomarker and EpitogenX Strategic Co-Development Agreement. More information.

Second Market: Bacterial–Viral Differentiation

Rapid differentiation between bacterial and viral infection is a major unmet clinical need. Misdiagnosis contributes to antibiotic overuse, unnecessary referrals, and avoidable treatment delays, sometimes leading to sepsis and unnecessary loss of life.

Diagnostic demand in this market is significant, and identified by the World Health Organisation as one of the single biggest threats to global health:

Attomarker is developing a multiplex spectrum test to measure biomarker signatures associated with bacterial and viral immune activation. This will support faster, more accurate decision-making in primary and urgent care settings, in as little as 7 minutes.

This represents the company’s second major commercial market.

Regulatory & Hardware Summary

Hardware Roadmap: From Benchtop to Handheld

Current tests are developed for the Liscar 6 benchtop point-of-care device, which already holds a CE mark. This device supports high-precision multiplex measurement across multiple biomarkers.

To meet the growing demand for at-home and consumer diagnostics, Attomarker is also developing a handheld device capable of running multiplex assays outside clinical settings. This reflects a global shift toward decentralised, consumer-led health testing and positions the company for future expansion into the home diagnostics market.

Attomarker Handheld Device (in design for manufacture)

Regulatory Strategy

Attomarker’s regulatory pathway supports entry into the UK, US, and European markets, beginning with Long Covid.

United States

Attomarker will introduce its Covid Antibody Spectrum Test through CLIA-certified partner laboratories, enabling compliant deployment as a laboratory-developed test (LDT). Real-world evidence gathered during laboratory use will inform whether a future FDA submission is required for broader commercialisation.

United Kingdom

• Covid Antibody Spectrum Test carries a UKCA mark for use in UK.
• The Liscar 6 analyser holds a CE mark.

Europe

Attomarker plans to pursue a full CE mark for CoAST, enabling wider European adoption under the IVDR framework.

This phased approach allows early commercialisation while building the regulatory foundation for wider diagnostic expansion.

Commercial Progress

• Covid Antibody Spectrum Test operational in the UK through Attomarker’s laboratory
• Strong clinical and patient demand from Long Covid communities from Hong Kong to Seattle
• Peer-reviewed publications supporting antibody kinetics, variant-specific immunity, and immune endotype analysis
• Pipeline assays under development for immune status, Spike protein detection, and IgG spectrum profiling
• Multiplex technology platform architected for scalable assay development
• Hardware roadmap positioned for both clinical and consumer markets

Retail Investors

Retail investors must complete all investment activity through Crowdcube.

Attomarker is engaged in an Acceleration Round which includes access through Crowdcube for retail investors. Eligible retail investors will be able to review the full pitch, risk information, and investment documents on the authorised platform. We are not able to support retail investors who are not eligible through Crowdcube e.g. because of their jurisdiction.

Investment Updates

You may register for investor and investment updates by completing the short form below. We will only use your details for this express purpose.

Register for Updates

Email of use

Name *

First

Last

Email *

Country of Residence *--- Select Choice ---United KingdomUnited StatesAndorraAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeneluxBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBruneiBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCanary IslandsCayman IslandsCentral African RepublicCentral AsiaChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo (Democratic Republic of the)Cook IslandsCosta RicaCôte dIvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland Islands [Malvinas]Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaInternationalIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea (the Democratic Peoples Republic of)Korea (the Republic of)KosovoKuwaitKyrgyzstanLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMelanesiaMexicoMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinePanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPolynesiaPortugalPuerto RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaScandinaviaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands (British)Virgin Islands (U.S.)Wallis and FutunaYemenZambiaZimbabwe

This is collected purely for regulatory compliance purposes.

Consent for use of information *

• Yes. I consent to the use of my submitted information for the purpose of Investor Updates

You may unsubscribe at any time from any email we send you.

Register for Updates

Professional, Angel and Institutional Investors

This section is intended for:

This section is intended for professional, institutional, high net worth, and sophisticated investors.

Attomarker Limited is a UK-based company. Any investment-related information made available through this site is provided for information purposes only and is not directed at retail investors. Access to detailed investment materials is restricted. Investors are asked to self-certify their status in line with UK financial promotion standards and to confirm their understanding of the risks associated with early-stage investments. If you believe you meet the criteria below, you may request access to further information by completing the confirmation below.

Stage 1 – Eligibility Confirmation

SECTION A: Investor Classification

Investor Classifications (required, at least one) *

• High Net Worth Individual (as defined under UK financial promotion rules)
• Self-Certified Sophisticated Investor
• Certified Sophisticated Investor
• Institutional or Professional Investor

Please confirm which of the following best describes you. This information is used to determine eligibility to access restricted investment materials.

SECTION B: Mandatory Acknowledgement

Investor Classification Confirmation *

• I confirm that I am not a retail investor and that I understand the nature of the information I will receive.

I understand that any information I may receive is intended only for high net worth, sophisticated, or professional investors and that early-stage investments involve significant risk.

SECTION C: Contact Details

Name *

First

Last

Email *

Organisation

If Individual, please leave blank.

CapacityIndividualAuthorised Signatory

Country Contact B:

Country of Residence *--- Select Choice ---United KingdomUnited StatesAndorraAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeneluxBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBruneiBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCanary IslandsCayman IslandsCentral African RepublicCentral AsiaChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo (Democratic Republic of the)Cook IslandsCosta RicaCôte dIvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland Islands [Malvinas]Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaInternationalIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea (the Democratic Peoples Republic of)Korea (the Republic of)KosovoKuwaitKyrgyzstanLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMelanesiaMexicoMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinePanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPolynesiaPortugalPuerto RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaScandinaviaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands (British)Virgin Islands (U.S.)Wallis and FutunaYemenZambiaZimbabwe

Collected for internal record-keeping and follow-up only. Country is not used to determine eligibility at this stage.

Submit & Proceed to Confidentiality Agreement